PTC Therapeutics (PTCT) said Friday that the European Commission has adopted the recommendation of the Committee for Medicinal Products for Human Use to not renew Translarna's marketing authorization for nonsense mutation Duchenne muscular dystrophy.
The commission indicated that under EU Directive 2001/83, individual member states in the European Union can still allow continued use of Translarna, the company said.
PTC Therapeutics said it plans to work on a country-by-country basis to continue marketing
Translarna, or ataluren, for Duchenne muscular dystrophy in the region.
Price: 54.98, Change: -0.01, Percent Change: -0.02
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。